Journals / Eurasian Journal of Medicine / 2019 / Cilt: 51 - Sayı: 1

Evaluation of 22 Primary Gastrointestinal Lymphoma Patients

Pages
53–56
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Mean overall survival time was determined significantly longer in small bowel group than gastric group (119±15 vs. 50±24 months) (p=0.039).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Primary gastrointestinal non-hodgkin lymphomas (PGI-NHL) are uncommon diseases with treatment modalities including chemotherapy, surgery, and radiotherapy.
📊
Key Findings & Data:Our aim is to analyze the demographic and clinical features and treatment results of PGI-NHL.Materials and Methods: 286 patients diagnosed with lymphoma who referred to Ataturk University Medical Faculty Hospital between July 2001 and April 2014 were surveyed retrospectively and 22 (7.6%) PGI-NHL cases whose primary lesions were in gastrointestinal system were included.Results: Mean age was 47 (min.25- max.77) and 14 (63.6%) of them were men.
💡
Conclusion & Impact:Mean overall survival time was determined significantly longer in small bowel group than gastric group (119±15 vs. 50±24 months) (p=0.039).
🔬Design:Survey & Empirical Study
📍Scope:2001 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: Primary gastrointestinal non-hodgkin lymphomas (PGI-NHL) are uncommon diseases with treatment modalities including chemotherapy, surgery, and radiotherapy. Our aim is to analyze the demographic and clinical features and treatment results of PGI-NHL.Materials and Methods: 286 patients diagnosed with lymphoma who referred to Ataturk University Medical Faculty Hospital between July 2001 and April 2014 were surveyed retrospectively and 22 (7.6%) PGI-NHL cases whose primary lesions were in gastrointestinal system were included.Results: Mean age was 47 (min.25- max.77) and 14 (63.6%) of them were men. The origin was determined as small intestines (50%), stomach (31.8%) and colon (18.2%), respectively. The most common complaint and pathologic subtype were abdominal pain (68.2%) and diffuse large B cell lymphoma (86.4%), respectively. The Lugano Classification was as follows: stage 1 (18.2%), stage 2 (59.1%), and stage 4 (22.7%). Surgery and chemotherapy were administered to 40.9% of patients. Complete and partial response and disease progression were established in 72.1%, 4.5% and 13.6% of the patients, respectively. Mean survival time was 99.6±16 months. Mean overall survival time was determined significantly longer in small bowel group than gastric group (119±15 vs. 50±24 months) (p=0.039). Age, gender, Eastern Cooperative Oncology Group performance status, International Prognostic Index, stage, histological type, tumor size, LDH level, albumin level, Hemoglobin level and treatment options were not associated with survival.Conclusion: Demographic and clinical characteristics of our series were similar with Middle Eastern and African countries. Optimal treatment options or prognostic factors for PGI-NHL are not clear. There is a need for randomized prospective studies including large number of patients and long follow-up period.

🔖

Cite This Article

AKDEMİR, M. N., ŞİMŞEK, M., TEKİN, S. B., YILDIRIM, N., TURKELİ, M. (2022). Evaluation of 22 Primary Gastrointestinal Lymphoma Patients. Eurasian Journal of Medicine, Cilt: 51 - Sayı: 1, 53–56. https://ajindex.com/articles/509375

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (4)

  1. Billroth T. Multipl lymphoma. Erfolgreiche behandlung mit arsenik. Wien Med Wochenschr 1871; 21: 1066
  2. Thomas CR, Share B. Gastrointestinal lymphoma. Med Ped Oncol 1991; 19: 48-60. [CrossRef] 3. Koch P, del Valle F, Berdel WE, et al. German Multicenter Study Group. Primary gastrointestinal non-Hodgkin’s lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01/92. J Clin Oncol 2001; 19: 3861-73. [CrossRef] 4. Erkurt MA, Aydogdu I, Kuku I, et al. Clinicopathologic characteristics and therapeutic outcomes of primary gastrointestinal non-Hodgkin’s lymphomas: 10 years of experience from a single center in eastern Anatolia. Med Princ Pract 2009; 18: 399-406. [CrossRef] 5. Eser B, Kaplan B, Unal A, et al. Clinicopathologic characteristics and therapeutic outcomes of primary gastrointestinal non-Hodgkin’s lymphomas in central Anatolia, in Turkey. Yonsei Med J 2006; 47: 22-33. [CrossRef] 6. Nakamura S, Matsumoto T, Iida M, Yao T, Tsuneyoshi M. Primary gastrointestinal lymphoma in Japan: a clinicopathologic analysis of 455 patients with special reference to its time trends. Cancer 2003; 97: 2462-73. [CrossRef] 7. Muller AM, Ihorst G, Mertelsmann R, Engelhardt M. Epidemiology of non-Hodgkin’s lymphoma (NHL): trends, geographic distribution, and etiology. Ann Hematol 2005; 84: 1-12. [CrossRef] 8. Dıng D, Peı W, Chen W, Zou Y, Ren S. Analysis of clinical characteristics, diagnosis, treatment and prognosis of 46 patients with primary gastrointestinal non-Hodgkin lymhoma. Molecular and Clin Oncol 2014; 2: 259-64. [CrossRef] 9. Li Minrui, Zhang S, Gu F, et al. Clinicopathological characteristics and prognostic factors of primary gastrointestinal lymphoma: a 22-year experience from South China Int J Clin Exp Pathol 2014; 7: 2718-28
  3. Lewin KJ, Ranchod M, Dorfman RF. Lymphomas of the gastrointestinal tract: a study of 117 cases presenting with gastrointestinal disease. Cancer 1978; 42: 693-707. [CrossRef] 11. Rohatiner A, d’Amore F, Coiffier B, et al. Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol 1994; 5: 397-400. [CrossRef] 12. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues. 4th edition. IARC Press; Lyon: 2008
  4. A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognosti